M&T Bank’s AbbVie ABBV Stock Holding History

M&T Bank’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205M	Sell	941,726 -33,261	-3%	-$7.38M	0.7%	27
2025 Q4	$223M	Buy	974,987 +19,378	+2%	+$4.41M	0.72%	28
2025 Q3	$221M	Buy	955,609 +33,271	+4%	+$6.78M	0.74%	29
2025 Q2	$171M	Sell	922,338 -19,972	-2%	-$3.71M	0.59%	36
2025 Q1	$197M	Sell	942,310 -35,085	-4%	-$6.82M	0.72%	29
2024 Q4	$174M	Sell	977,395 -18,922	-2%	-$3.48M	0.58%	35
2024 Q3	$197M	Sell	996,317 -43,097	-4%	-$8.04M	0.65%	33
2024 Q2	$178M	Buy	1,039,414 +59,969	+6%	+$9.93M	0.61%	36
2024 Q1	$178M	Buy	979,445 +12,865	+1%	+$2.22M	0.62%	33
2023 Q4	$150M	Buy	966,580 +3,496	+0.4%	+$510K	0.55%	39
2023 Q3	$144M	Buy	963,084 +10,105	+1%	+$1.48M	0.57%	38
2023 Q2	$128M	Buy	952,979 +138,661	+17%	+$20.3M	0.48%	42
2023 Q1	$130M	Buy	814,318 +78,076	+11%	+$11.9M	0.5%	44
2022 Q4	$119M	Buy	736,242 +4,517	+0.6%	+$693K	0.48%	50
2022 Q3	$98.2M	Buy	731,725 +19,198	+3%	+$2.75M	0.44%	55
2022 Q2	$103M	Buy	712,527 +36,878	+5%	+$5.64M	0.49%	46
2022 Q1	$110M	Buy	675,649 +4,209	+0.6%	+$611K	0.48%	47
2021 Q4	$90.9M	Sell	671,440 -1,036	-0.2%	-$122K	0.38%	65
2021 Q3	$72.5M	Sell	672,476 -7,856	-1%	-$898K	0.33%	76
2021 Q2	$76.6M	Sell	680,332 -26,980	-4%	-$3.04M	0.34%	73
2021 Q1	$76.5M	Sell	707,312 -39,526	-5%	-$4.23M	0.33%	73
2020 Q4	$80M	Sell	746,838 -32,031	-4%	-$3.08M	0.35%	67
2020 Q3	$68.2M	Buy	778,869 +14,928	+2%	+$1.41M	0.33%	66
2020 Q2	$75M	Buy	763,941 +18,257	+2%	+$1.61M	0.4%	56
2020 Q1	$56.8M	Sell	745,684 -25,937	-3%	-$2.21M	0.34%	75
2019 Q4	$68.3M	Buy	771,621 +2,352	+0.3%	+$195K	0.32%	60
2019 Q3	$58.3M	Sell	769,269 -36,382	-5%	-$2.49M	0.29%	91
2019 Q2	$58.6M	Sell	805,651 -223,901	-22%	-$17.6M	0.31%	94
2019 Q1	$83M	Sell	1,029,552 -132,738	-11%	-$10.9M	0.43%	54
2018 Q4	$107M	Sell	1,162,290 -41,874	-3%	-$3.68M	0.62%	36
2018 Q3	$114M	Sell	1,204,164 -26,089	-2%	-$2.47M	0.57%	38
2018 Q2	$114M	Sell	1,230,253 -2,603	-0.2%	-$254K	0.61%	35
2018 Q1	$117M	Sell	1,232,856 -41,920	-3%	-$4.6M	0.63%	36
2017 Q4	$123M	Sell	1,274,776 -30,769	-2%	-$2.9M	0.65%	34
2017 Q3	$116M	Buy	1,305,545 +20,970	+2%	+$1.6M	0.63%	35
2017 Q2	$93.1M	Buy	1,284,575 +22,667	+2%	+$1.52M	0.55%	40
2017 Q1	$82.2M	Sell	1,261,908 -50,755	-4%	-$3.19M	0.5%	44
2016 Q4	$82.2M	Buy	1,312,663 +168,546	+15%	+$10.3M	0.51%	43
2016 Q3	$72.2M	Sell	1,144,117 -12,681	-1%	-$821K	0.46%	48
2016 Q2	$71.6M	Buy	1,156,798 +15,971	+1%	+$973K	0.48%	46
2016 Q1	$65.2M	Buy	1,140,827 +165,085	+17%	+$9.2M	0.44%	54
2015 Q4	$57.8M	Buy	975,742 +663	+0.1%	+$38.2K	0.38%	64
2015 Q3	$53.1M	Buy	975,079 +30,149	+3%	+$1.96M	0.36%	66
2015 Q2	$63.5M	Sell	944,930 -638	-0.1%	-$41.7K	0.38%	59
2015 Q1	$55.4M	Buy	945,568 +13,574	+1%	+$820K	0.35%	66
2014 Q4	$61M	Buy	931,994 +15,824	+2%	+$998K	0.38%	56
2014 Q3	$52.9M	Buy	916,170 +757,816	+479%	+$42.1M	0.34%	60
2014 Q2	$8.94M	Sell	158,354 -4,686	-3%	-$246K	0.37%	58
2014 Q1	$8.38M	Sell	163,040 -10,539	-6%	-$533K	0.35%	66
2013 Q4	$9.17M	Sell	173,579 -4,577	-3%	-$225K	0.38%	58
2013 Q3	$7.97M	Sell	178,156 -4,615	-3%	-$205K	0.38%	60
2013 Q2	$7.56M	Buy	+182,771	New	+$7.99M	0.37%	63

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

M&T Bank's ABBV Position: Q1 2026 in Review

M&T Bank reduced its AbbVie (ABBV) stake by 3.4% in Q1 2026, selling an estimated $7.38M and leaving 941,726 shares worth $205M. The position accounts for 0.7% of the portfolio, ranked #27.

M&T Bank first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $223M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

M&T Bank held 941,726 shares of AbbVie worth $205M as of Q1 2026.
M&T Bank sold 33,261 AbbVie shares in Q1 2026, an estimated $7.38M.
AbbVie made up 0.7% of M&T Bank's portfolio in Q1 2026, its #27 holding.
M&T Bank first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
M&T Bank's AbbVie position peaked at $223M in Q4 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.